Literature DB >> 3887571

Qinghaosu (artemisinin): an antimalarial drug from China.

D L Klayman.   

Abstract

The herb Artemisia annua has been used for many centuries in Chinese traditional medicine as a treatment for fever and malaria. In 1971, Chinese chemists isolated from the leafy portions of the plant the substance responsible for its reputed medicinal action. This compound, called qinghaosu (QHS, artemisinin), is a sesquiterpene lactone that bears a peroxide grouping and, unlike most other antimalarials, lacks a nitrogen-containing heterocyclic ring system. The compound has been used successfully in several thousand malaria patients in China, including those with both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Derivatives of QHS, such as dihydroqinghaosu, artemether, and the water-soluble sodium artesunate, appear to be more potent than QHS itself. Sodium artesunate acts rapidly in restoring to consciousness comatose patients with cerebral malaria. Thus QHS and its derivatives offer promise as a totally new class of antimalarials.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887571     DOI: 10.1126/science.3887571

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  303 in total

1.  Antimalarial activity of synthetic 1,2,4-trioxanes and cyclic peroxy ketals, a quantum similarity study.

Authors:  X Gironés; A Gallegos; R Carbó-Dorca
Journal:  J Comput Aided Mol Des       Date:  2001-12       Impact factor: 3.686

2.  Reaction of artemisinin with haemoglobin: implications for antimalarial activity.

Authors:  Rangiah Kannan; Krishan Kumar; Dinkar Sahal; Shrikant Kukreti; Virander S Chauhan
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

3.  Establishment of an in vitro screening model for neurodegeneration induced by antimalarial drugs of the artemisinin-type..

Authors:  G Schmuck; R K Haynes
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine.

Authors:  Youyou Tu
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

5.  Synthesis and biological evaluation of 1,4-naphthoquinones and quinoline-5,8-diones as antimalarial and schistosomicidal agents.

Authors:  Don Antoine Lanfranchi; Elena Cesar-Rodo; Benoît Bertrand; Hsin-Hung Huang; Latasha Day; Laure Johann; Mourad Elhabiri; Katja Becker; David L Williams; Elisabeth Davioud-Charvet
Journal:  Org Biomol Chem       Date:  2012-07-10       Impact factor: 3.876

6.  Predicting Productive Binding Modes for Substrates and Carbocation Intermediates in Terpene Synthases-Bornyl Diphosphate Synthase as a Representative Case.

Authors:  Terrence E O'Brien; Steven J Bertolani; Yue Zhang; Justin B Siegel; Dean J Tantillo
Journal:  ACS Catal       Date:  2018-03-08       Impact factor: 13.084

7.  Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand.

Authors:  S Krudsood; K Chalermrut; C Pengruksa; S Srivilairit; U Silachamroon; S Treeprasertsuk; S Kano; G M Brittenham; S Looareesuwan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-06       Impact factor: 0.267

8.  In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni.

Authors:  S H Xiao; B A Catto
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.

Authors:  Fengyun Dong; Xia Zhou; Changsheng Li; Suhua Yan; Xianming Deng; Zhiqun Cao; Liqun Li; Bo Tang; Thaddeus D Allen; Ju Liu
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 10.  New antimalarials. A risk-benefit analysis.

Authors:  F Nosten; R N Price
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.